Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camillo Porta

Showing results (1-10 of 426) with videos related to

Pageof 43
Sort By:
Future Oncology (London, England)|December 14, 2011
The European Multidisciplinary Cancer Congress (ECCO 16, ESMO 36 and ESTRO 30)Camillo Porta
Oncology Reviews|May 12, 2020
RETRACTION: The biological mechanism involved in anticancer properties of amniotic membraneCamillo Porta
European Urology|August 4, 2012
How to identify active novel agents in rare cancers and then make them available: a need for a paradigm shiftCamillo Porta
Cancer Treatment Reviews|March 7, 2006
Adding raltitrexed to cisplatin improves overall survival in people with malignant pleural mesotheliomaCamillo Porta
European Urology|August 9, 2011
Entropy increases in kidney cancer treatment, but a bit of simplicity may emerge from chaosCamillo Porta
Expert Review of Anticancer Therapy|December 27, 2005
Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancerCamillo Porta
ESMO Open|May 6, 2020
Editorial debate: Challenges an oncologist has to face during the SARS-CoV-2 pandemic within a universal healthcare systemCamillo Porta
Medical Oncology (Northwood, London, England)|October 4, 2011
Sequential therapy in metastatic renal cell carcinoma: what comes next?Camillo Porta, Thomas Powles
BJU International|March 2, 2011
Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centreCamillo Porta, Chiara Paglino
Oncology Reviews|October 20, 2021
Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?Francesca Negri, Camillo Porta
Pageof 43

Showing results (1-10 of 426) with videos related to

Sort By:
Pageof 43
Future Oncology (London, England)|December 14, 2011
The European Multidisciplinary Cancer Congress (ECCO 16, ESMO 36 and ESTRO 30)Camillo Porta
Oncology Reviews|May 12, 2020
RETRACTION: The biological mechanism involved in anticancer properties of amniotic membraneCamillo Porta
European Urology|August 4, 2012
How to identify active novel agents in rare cancers and then make them available: a need for a paradigm shiftCamillo Porta
Cancer Treatment Reviews|March 7, 2006
Adding raltitrexed to cisplatin improves overall survival in people with malignant pleural mesotheliomaCamillo Porta
European Urology|August 9, 2011
Entropy increases in kidney cancer treatment, but a bit of simplicity may emerge from chaosCamillo Porta
Expert Review of Anticancer Therapy|December 27, 2005
Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancerCamillo Porta
ESMO Open|May 6, 2020
Editorial debate: Challenges an oncologist has to face during the SARS-CoV-2 pandemic within a universal healthcare systemCamillo Porta
Medical Oncology (Northwood, London, England)|October 4, 2011
Sequential therapy in metastatic renal cell carcinoma: what comes next?Camillo Porta, Thomas Powles
BJU International|March 2, 2011
Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centreCamillo Porta, Chiara Paglino
Oncology Reviews|October 20, 2021
Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?Francesca Negri, Camillo Porta
Pageof 43